Phase III Study of Oral REVLIMIDA in Newly-Diagnosed Multiple Myeloma Meets Primary Endpoint Celgene International SA rl, a wholly-owned subsidiary of Celgene Corporation , today announced that its phase III study of REVLIMID A in combination with dexamethasone in patients newly diagnosed with multiple myeloma met its primary endpoint of ... (more)
http://www.pr-inside.com/phase-iii-study-mm-020ifm-07-01-of-r3731522.htm
http://www.pr-inside.com/phase-iii-study-mm-020ifm-07-01-of-r3731522.htm
No comments:
Post a Comment